Helios 5.8 mg

Helios 5.8 mg contains Clenbuterol and Yohimbine, both of which are veterinary medications. Clenbuterol is approved for management of airway obstruction in horses, and Yohimbine is approved for reversing xylazine sedation in dogs and deer. In non-medical bodybuilding settings, Helios 5.8 mg is commonly referenced for localized fat reduction, though such use falls outside approved indications.

In non-medical bodybuilding contexts, Helios is commonly referenced as being administered at 0.5 mL per day initially, with gradual increases up to a maximum of approximately 2 mL per day. Injections are typically performed once or twice daily into areas of stubborn fat accumulation. Use is commonly limited to cycles of up to 4 weeks.

Helios 5.8 mg does not contain hormonal compounds and does not suppress endogenous testosterone production, so post-cycle therapy is not typically required after use. However, if Helios is used as part of a broader cycle that includes anabolic steroids, PCT protocols would be determined by the other compounds used. Agents such as Clomid or Nolvadex may be referenced in such contexts.

Clenbuterol is a beta-2 adrenergic agonist that provides bronchodilating properties. In horses, it is indicated for the management of airway obstruction such as occurs in chronic obstructive pulmonary disease. In bodybuilding contexts, it is commonly referenced for its thermogenic effects and ability to stimulate fat cell metabolism.

Yohimbine is an alpha-2 adrenergic antagonist. In veterinary medicine, it is used to reverse the effects of xylazine sedation in dogs and deer. In bodybuilding contexts, it is commonly referenced for its ability to block alpha-2 receptors, which may promote increased norepinephrine release and support fat mobilization.

In non-medical bodybuilding contexts, users typically report noticing stimulant effects such as increased heart rate and sweating within the first few days of use. Fat loss effects are generally referenced as becoming noticeable over a period of several weeks, with results varying based on diet, training, and individual response.

There is no single product that is universally best for fat loss. Helios 5.8 mg is a specialized injectable combination of two adrenergic compounds that is commonly referenced for localized fat reduction in bodybuilding contexts. Other products such as Clenbuterol and T3 are also referenced for fat loss purposes.

Helios 5.8 mg is an injectable combination of Clenbuterol and Yohimbine, while Clenbuterol is a single-compound product. The addition of Yohimbine provides alpha-2 antagonist activity alongside Clenbuterol's beta-2 agonist effects. This combination is designed for potential localized fat reduction applications.

The "5.8 mg" in the product name refers to the combined concentration of Clenbuterol (30 mcg) and Yohimbine (5.6 mg) per mL. A milligram amount cannot be classified as appropriate or excessive without considering the specific context and individual tolerance. In non-medical contexts, starting doses of 0.5 mL per day are commonly referenced.

Helios 5.8 mg is labeled at Clenbuterol 30 mcg and Yohimbine 5.6 mg per mL. It is supplied in a 10 mL vial, giving a total of 300 mcg Clenbuterol and 56 mg Yohimbine per vial.

Yes. A published laboratory report dated November 20, 2025 measured Helios 5.8 mg at Clenbuterol 43.28 mcg and Yohimbine 5.27 mg, equivalent to 144.3% and 94.1% of label claim respectively.

The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.

The published laboratory report for Helios 5.8 mg references batch HELIBG9, tested on November 20, 2025. The measured results for that sample were Clenbuterol 43.28 mcg and Yohimbine 5.27 mg.